Sting1^{tm1c(EUCOMM)Hmgu}
Targeted Allele Detail

Summary

• Symbol: Sting1^{tm1c(EUCOMM)Hmgu}
• Name: stimulator of interferon response cGAMP interactor 1; targeted mutation 1c, Helmholtz Zentrum Muenchen GmbH
• MGI ID: MGI:7514173
• Synonyms: STING^flox
• Gene: Sting1 Location: Chr18:35866732-35873607 bp, - strand Genetic Position: Chr18, 19.23 cM, cytoband B3
• Alliance: Sting1^{tm1c(EUCOMM)Hmgu} page
• IMPC: Sting1 gene page

Mutation origin

• Germline Transmission: Earliest citation of germline transmission: J:307921
• Parent Cell Line: JM8A3.N1 (ES Cell)
• Strain of Origin: C57BL/6N-A^tm1Brd
• Project Collection: EUCOMM

Mutation description

• Allele Type: Targeted (Conditional ready)
• Mutation: Insertion
• Mutation details: The L1L2_GT1_LF2A_LacZ_BetactP_neo cassette was inserted at position 35868570 of Chromosome 18 upstream of the critical exon(s) (Build GRCm39). The cassette is composed of an FRT site followed by lacZ sequence and a loxP site. This first loxP site is followed by a neomycin resistance gene under the control of the human beta-actin promoter, SV40 polyA, a second FRT site and a second loxP site. A third loxP site is inserted downstream of the targeted exon(s) at position 35869639. The critical exon(s) is/are thus flanked by loxP sites. A "conditional ready" (floxed) allele was created by flp recombinase expression in mice carrying this allele to remove the lacZ sequence and neo selection cassette, leaving loxP sites flanking the critical exon(s). Further information on targeting strategies used for this and other IKMC alleles can be found at http://www.informatics.jax.org/mgihome/nomen/IKMC_schematics.shtml (J:307921)

Find Mice (IMSR)

• Mouse strains and cell lines available from the International Mouse Strain Resource (IMSR)
• Carrying this Mutation: Mouse Strains: 0 strains available Cell Lines: 0 lines available
• Carrying any Sting1 Mutation: 51 strains or lines available

References

• Original: J:307921 Jeong SH, et al., Refractoriness of STING therapy is relieved by AKT inhibitor through effective vascular disruption in tumour. Nat Commun. 2021 Jul 20;12(1):4405
• All: 1 reference(s)